Sagimet Biosciences (SGMT) News Today $4.52 +0.11 (+2.49%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Sagimet Biosciences participates ik,on NoNovember 20 at 7:50 AM | markets.businessinsider.comSagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024November 18 at 11:38 PM | markets.businessinsider.comSagimet Biosciences presents clinical denifanstat, preclinical FASN inhibitor daNovember 18 at 11:38 PM | markets.businessinsider.comSagimet Biosciences Inc. Reports Financial Results for Q3 2024 and Regulatory ProgressNovember 18 at 4:11 AM | americanbankingnews.comPromising Outlook for Sagimet Biosciences: Buy Rating Driven by Denifanstat’s Clinical Success and Phase 3 MASH Program InitiationNovember 16, 2024 | markets.businessinsider.comSagimet Biosciences (NASDAQ:SGMT) Earns "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $32.00 target price on shares of Sagimet Biosciences in a research report on Friday.November 15, 2024 | marketbeat.comSagimet Biosciences, Inc.: Strategic Advancements and Financial Robustness Drive Buy RatingNovember 15, 2024 | markets.businessinsider.comBrokerages Set Sagimet Biosciences Inc. (NASDAQ:SGMT) Target Price at $24.00November 15, 2024 | americanbankingnews.comSagimet Biosciences reports Q3 EPS (45c) vs (35c) last yearNovember 14, 2024 | markets.businessinsider.comSagimet: More Than Just A MASH Drug Development BiotechNovember 14, 2024 | seekingalpha.comSagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesNovember 14, 2024 | finance.yahoo.comSagimet draws buy at UBS on MASH opportunityNovember 13, 2024 | seekingalpha.comUBS Initiates Coverage of Sagimet Biosciences (SGMT) with Buy RecommendationNovember 13, 2024 | msn.comSagimet Biosciences: Promising Drug Denifanstat and Market Potential Drive Buy RatingNovember 12, 2024 | markets.businessinsider.comSagimet Biosciences initiated with a Buy at UBSNovember 12, 2024 | markets.businessinsider.comSagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five analysts that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and four have assignedNovember 12, 2024 | marketbeat.comSagimet Biosciences (NASDAQ:SGMT) Coverage Initiated by Analysts at UBS GroupUBS Group started coverage on Sagimet Biosciences in a research note on Tuesday. They issued a "buy" rating and a $12.00 price target on the stock.November 12, 2024 | marketbeat.comAscletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of AcneNovember 12, 2024 | prnewswire.comSagimet Biosciences to Participate in the UBS Global Healthcare ConferenceNovember 8, 2024 | markets.businessinsider.comSagimet’s denifanstat enters Phase III trials for MASH treatmentNovember 1, 2024 | msn.comSagimet Biosciences, Inc. Class A (SGMT) Receives a Rating Update from a Top AnalystOctober 31, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Sagimet Biosciences, Inc. Class A (SGMT), Boston Scientific (BSX)October 31, 2024 | markets.businessinsider.comSagimet Biosciences (NASDAQ:SGMT) Receives Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $32.00 target price on shares of Sagimet Biosciences in a research note on Thursday.October 31, 2024 | marketbeat.comSagimet Biosciences completes End-of-Phase 2 meeting with FDA on denifanstatOctober 30, 2024 | markets.businessinsider.comShort Interest in Sagimet Biosciences Inc. (NASDAQ:SGMT) Grows By 102.0%Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) was the recipient of a large growth in short interest in October. As of October 15th, there was short interest totalling 3,980,000 shares, a growth of 102.0% from the September 30th total of 1,970,000 shares. Approximately 18.8% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,310,000 shares, the days-to-cover ratio is presently 3.0 days.October 26, 2024 | marketbeat.comSagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate DenifanstatOctober 19, 2024 | seekingalpha.comSagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024October 16, 2024 | finance.yahoo.comSagimet Gains on Latest NumbersOctober 11, 2024 | baystreet.caSagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & HepatologyOctober 11, 2024 | globenewswire.comSagimet Biosciences Inc. (NASDAQ:SGMT) Shares Sold by Renaissance Technologies LLCRenaissance Technologies LLC reduced its holdings in shares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) by 42.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 242,400 shares of the company's stoOctober 8, 2024 | marketbeat.comSagimet Biosciences’ Denifanstat Receives Buy Rating on FDA’s BTD and Promising Trial ResultsOctober 4, 2024 | markets.businessinsider.comLeerink maintains Sagimet Biosciences shares at Outperform ratingOctober 3, 2024 | uk.investing.com3 Penny Stocks to Watch Now, 10/3/24October 3, 2024 | msn.comSagimet Biosciences (NASDAQ:SGMT) Stock Quotes, Forecast and News SummaryOctober 2, 2024 | benzinga.comBuy Rating for Sagimet Biosciences on Strong Phase 2b Results and Favorable Valuation ModelOctober 2, 2024 | markets.businessinsider.comSagimet Biosciences Inc. (NASDAQ:SGMT) Shares Sold by Point72 Asset Management L.P.Point72 Asset Management L.P. decreased its holdings in Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) by 11.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,366,090 shares of the company's stoOctober 2, 2024 | marketbeat.comBuy Rating Justified: Sagimet Biosciences’ Denifanstat Poised to Transform NASH Treatment LandscapeOctober 1, 2024 | markets.businessinsider.comSagimet Shares Rise Premarket on FDA Breakthrough DesignationOctober 1, 2024 | marketwatch.comSagimet Biosciences Gets FDA Breakthrough Therapy Designation For DenifanstatOctober 1, 2024 | markets.businessinsider.comSagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASHOctober 1, 2024 | globenewswire.comSagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 1, 2024 | globenewswire.comSagimet Announces Oral Presentation at the 8th Annual MASH Drug Development SummitSeptember 12, 2024 | globenewswire.comSagimet Biosciences (NASDAQ:SGMT) Stock, Short Interest ReportSeptember 11, 2024 | benzinga.comSGMT Jan 2025 2.500 put (SGMT250117P00002500)August 26, 2024 | uk.finance.yahoo.comSGMT Apr 2025 7.500 call (SGMT250417C00007500)August 26, 2024 | uk.finance.yahoo.comSGMT Sep 2024 5.000 put (SGMT240920P00005000)August 26, 2024 | finance.yahoo.comSagimet Biosciences Inc. to Post Q3 2024 Earnings of ($0.52) Per Share, HC Wainwright Forecasts (NASDAQ:SGMT)Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) - Research analysts at HC Wainwright upped their Q3 2024 EPS estimates for Sagimet Biosciences in a research report issued on Thursday, August 15th. HC Wainwright analyst E. Arce now forecasts that the company will post earnings per share of ($August 19, 2024 | marketbeat.comVanguard Group Inc. Grows Stock Position in Sagimet Biosciences Inc. (NASDAQ:SGMT)Vanguard Group Inc. increased its stake in shares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) by 364.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,139,407 shares of the company's stocAugust 17, 2024 | marketbeat.comSGMT Sagimet Biosciences Inc.August 16, 2024 | seekingalpha.comBuy Rating Affirmed for Sagimet Biosciences on Robust Denifanstat Prospects and Strategic AdvancementsAugust 16, 2024 | markets.businessinsider.com Get Sagimet Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump won. Buy this coin now. (Ad)Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher. This could be his favorite coin. SGMT Media Mentions By Week SGMT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SGMT News Sentiment▼-0.070.46▲Average Medical News Sentiment SGMT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SGMT Articles This Week▼132▲SGMT Articles Average Week Get Sagimet Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Organogenesis News Today Corvus Pharmaceuticals News Today Altimmune News Today Sana Biotechnology News Today ProKidney News Today Monte Rosa Therapeutics News Today PureTech Health News Today Terns Pharmaceuticals News Today GH Research News Today Mereo BioPharma Group News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SGMT) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sagimet Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sagimet Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SGMT Stock Alerts